Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: A dose deescalation study

Transplantation

Volumn 78, Issue 3, 2004, Pages 352-359

  Bethge, Wolfgang A ^a,b   Wilbur, D Scott ^d   Storb, Rainer ^a,c   Hamlin, Donald K ^d   Santos, Erlinda B ^a   Brechbiel, Martin W ^e   Sandmaier, Brenda M ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Allogeneic hematopoietic cell transplantation; Nonmyeloablative; Radioimmunotherapy

Indexed keywords

BISMUTH 213; CYCLOSPORIN A; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTETIC ACID;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHIMERA; CONTROLLED STUDY; DOG; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; LIVER FUNCTION TEST; LIVER TOXICITY; MIXED LEUKOCYTE CULTURE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY;

ANIMALS; ANTIGENS, CD45; BISMUTH; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FLOW CYTOMETRY; IMMUNOTHERAPY; MODELS, ANIMAL; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 4143134313     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000128853.62545.B2     Document Type: Article

References (30)

1. Appelbaum FR, Brown P, Sandmaier B, et al. Antibody-radionuclide conjugates as part of a myeloablative preparative regimen for marrow transplantation. Blood 1989; 73: 2202-2208.
2. Bunjes D, Buchmann I, Duncker C, et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: Results of a phase I-II study. Blood 2001; 98: 565-572.
3. Matthews DC, Appelbaum FR, Eary JF, et al. Radiolabeled Anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque. Blood 1991; 78: 1864-1874.
4. Matthews DC, Appelbaum FR, Eary JF, et al. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 1995; 85: 1122-1131.
5. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048-3054.
6. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
7. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003; 102: 2021-2030.
8. Bethge WA, Wilbur DS, Storb R, et al. Selective T-cell ablation with bismuth-213-labeled anti-TCRαβ as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood 2003; 101: 5068-5075.
9. Sandmaier BM, Bethge WA, Wilbur DS, et al. Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood 2002; 100: 318-326.
10. Caniatti M, Roccabianca P, Scanziani E, et al. Canine lymphoma: Immunocytochemical analysis of fine-needle aspiration biopsy. Vet Pathol 1996; 33: 204-212.
11. Barsoukov AA, Moore PF, Storb R, et al. The use of an anti-TCRαβ monoclonal antibody to control host-versus-graft reactions in canine marrow allograft recipients conditioned with low dose total body irradiation. Transplantation 1999; 67: 1329-1335.
12. Moore PF, Rossitto PV, Danilenko DM, et al. Monoclonal antibodies specific for canine CD4 and CD8 define functional T-lymphocyte subsets and high density expression of CD4 by canine neutrophils. Tissue Antigens 1992; 40: 75-85.
13. Sandmaier BM, Storb R, Appelbaum FR, et al. An antibody that facilitates hematopoietic engraftment recognizes CD44. Blood 1990; 76: 630-635.
14. Sandmaier BM, Schuening FG, Bianco JA, et al. Biochemical characterization of a unique canine myeloid antigen. Leukemia 1991; 5: 125-130.
15. Denkers E, Badger CC, Ledbetter JA, et al. Influence of antibody isotype on passive serotherapy of lymphoma. J Immunol 1985; 135: 2183-2186.
16. Jacobsen CN, Aasted B, Broe MK, et al. Reactivities of 20 anti-human monoclonal antibodies with leucocytes from ten different animal species. Vet Immunol Immunopathol 1993; 39: 461-466.
17. Pippin CG, Parker TA, McMurry TJ, et al. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-mono-clonal antibody conjugates. Bioconjug Chem 1992; 3: 342-345.
18. Wagner JL, Burnett RC, DeRose SA, et al. Histocompatibility testing of dog families with highly polymorphic microsatellite markers. Transplantation 1996; 62: 876-877.
19. Wagner JL, Works JD, Storb R. DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing. Tissue Antigens 1998; 52: 397-401.
20. Loughran TP Jr, Deeg HJ, Storb R. Morphologic and phenotypic analysis of canine natural killer cells: Evidence for T-cell lineage. Cell Immunol 1985; 95: 207-217.
21. Raff RF, Deeg HJ, Farewell VT, et al. The canine major histocompatibility complex: Population study of DLA-D alleles using a panel of homozygous typing cells. Tissue Antigens 1983; 21: 360-373.
22. Bianco JA, Sandmaier B, Brown P, et al. Specific marrow localization of an 131I-labeled anti-myeloid antibody in normal dogs: Effects of a "cold" antibody pretreatment dose on marrow localization. Exp Hematol 1989; 17: 929-934.
23. Yu C, Ostrander E, Bryant E, et al. Use of (CA)n polymorphisms to determine the origin of blood cells after allogeneic canine marrow grafting. Transplantation 1994; 58: 701-706.
24. Ruffner KL, Martin PJ, Hussell S, et al. Immunosuppressive effects of 131I-anti-CD45 antibody in unsensitized and donor antigen-presensitized H2-matched, minor antigen-mismatched murine transplant models. Cancer Res 2001; 61: 5126-5131.
25. Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999; 94: 1237-1247.
26. Macklis RM, Kinsey BM, Kassis AI, et al. Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science 1988; 240: 1024-1026.
27. Abbas RS, Sarkar S, Goozee G, et al. Radioimmunoconjugates for targeted alpha therapy of malignant melanoma. Melanoma Res 2000; 10: 281-289.
28. Nikula TK, McDevitt MR, Finn RD, et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med 1999; 40: 166-176.
29. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002; 100: 1233-1239.
30. Jurcic JG. Antibody therapy for residual disease in acute myelogenous leukemia. Crit Rev Oncol Hematol 2001; 38: 37-45.